Latest Regulation News

Titomic Limited is gearing up for a strategic shift to the US with a planned redomicile in H2 2026, while clinching major contracts across aerospace, defense, and rail sectors and achieving critical certifications that underpin its manufacturing ambitions.

Alexium International Group has boosted sales to $1.03 million following its Microtek Laboratories acquisition, shifting focus to manufacturing-led growth and expanding its flame-retardant and thermal regulation product lines.

Metals X reported its fourth highest quarterly tin production at Renison with robust financials despite rising unit costs, while progressing the Rentails project and maintaining a strong cash position.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Zinc of Ireland NL is set to reshape its zinc recovery and battery recycling prospects after signing to acquire Meclex's innovative hydrometallurgical technologies and launching a major drilling campaign at its Kildare project.

African Gold Ltd has finalised its court-approved scheme of arrangement, transferring all shares and options to Montage Gold Corp and preparing for imminent ASX delisting.

European Metals Holdings has secured critical regulatory milestones for its Cinovec Lithium Project, submitting the full Environmental Impact Assessment and obtaining Regional Rezoning approval. The company also raised A$3.46 million to support ongoing development.

Clean TeQ Water boosted its cash position and operational momentum in Q3 FY26, winning a A$10.4 million DESALX execution contract at Nyrstar Belgium, completing a uranium plant at Heathgate Resources, and advancing lithium and phosphate projects internationally.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Thor Energy secured A$6.56 million from the Molyhil sale, expanded its natural hydrogen portfolio with new Otway Basin licences, and advanced its HY-Range Project geochemistry survey during Q1 2026.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.